What pharma news happened in January 2023?

71 regulatory actions across global regulators, 0 Phase 3 trial completions, and 2 patent expiries — all sourced from primary regulatory + USPTO + ClinicalTrials.gov.

How fresh is this archive?

Each month's archive solidifies as it passes — the current month updates every 30 minutes; past months are stable historical archives.

January 2023 — Pharma News Archive

Every regulatory action (71), Phase 3 readout (0), and patent expiry (2) tracked in January 2023. Sourced from Drugs@FDA, EMA EPAR, ClinicalTrials.gov, USPTO Orange Book.

71 regulatory actions 0 Phase 3 readouts 2 patent expiries

Regulatory actions (71)

2023-01-31 — OPC-34712 · FDA · approved · US · Otsuka Pharmaceutical Development & Commercialization, Inc. · Psychiatry/Neurology
2023-01-31 — Bacteriostatic Water For Injection In Plastic Container · FDA · approved · US · Pfizer Inc.
2023-01-31 — AGB101 · FDA · approved · US · AgeneBio · Neurology
2023-01-31 — Keppra · FDA · approved · US · Generic (originally UCB Pharma) · Metabolic
2023-01-31 — Sterile Water · FDA · approved · US · Pfizer
2023-01-30 — TECHNETIUM TC-99M · FDA · approved · US
2023-01-30 — Aminophylline group · FDA · approved · US · Tanta University
2023-01-30 — TC · FDA · approved · US · AGO Study Group · Oncology
2023-01-27 — Orserdu · MFDS · likely_approved · KR · Stemline Therap · Oncology
2023-01-27 — Capozide 25/15 · FDA · approved · US · Aarxion Anda Hlding · Metabolic
2023-01-27 — Orserdu · FDA · approved · US · Stemline Therap · Oncology
2023-01-27 — Orserdu · FDA · approved · US · Stemline Therap · Oncology
2023-01-27 — Parafon Forte Dsc · FDA · approved · US · Johnson & Johnson · Pain
2023-01-27 — Orserdu · MOH · likely_approved · IL · Stemline Therap · Oncology
2023-01-27 — Orserdu · HSA · likely_approved · SG · Stemline Therap · Oncology
2023-01-27 — Orserdu · SFDA · likely_approved · SA · Stemline Therap · Oncology
2023-01-27 — Orserdu · MOH · likely_approved · AE · Stemline Therap · Oncology
2023-01-27 — ACE inhibitors · FDA · approved · US · GlaxoSmithKline · Cardiovascular
2023-01-26 — Abiraterone Acetate · FDA · approved · US · Janssen Biotech · Oncology
2023-01-25 — Champix · FDA · approved · US · The Queen Elizabeth Hospital · Neuroscience
2023-01-24 — KETAMINE · FDA · approved · US
2023-01-24 — TIVA · FDA · approved · US · Ain Shams University · Other
2023-01-24 — Ketalar · FDA · approved · US · Ph Health · Metabolic
2023-01-24 — Entereg · FDA · approved · US · Cubist Pharms · Pain
2023-01-23 — Bismuth quadruple therapy · FDA · approved · US · Zhongda Hospital · Infectious Disease
2023-01-23 — Metro I.V. In Plastic Container · FDA · approved · US · Baxter · Immunology
2023-01-20 — Administration of Vancomycin · FDA · approved · US · University of Colorado, Denver · Infectious Disease
2023-01-20 — Brenzavvy · FDA · approved · US · Theracosbio · Metabolic
2023-01-19 — Rapamune · FDA · approved · US · Pfizer · Oncology
2023-01-19 — SIROLIMUS · FDA · approved · US
2023-01-18 — Unithroid · FDA · approved · US · Fresenius Kabi · Oncology
2023-01-18 — Benicar · FDA · approved · US · Cosette · Metabolic
2023-01-18 — Remeron · FDA · approved · US · Generic (originally Organon/MSD) · Neuroscience
2023-01-18 — COLESEVELAM HYDROCHLORIDE · FDA · approved · US
2023-01-18 — Neurontin · FDA · approved · US · Generic (originally Parke-Davis/Pfizer) · Neuroscience
2023-01-18 — Test Euthyrox® · FDA · approved · US · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
2023-01-18 — Losartan, Losartan and HCTZ, Amlodipine , Spironolactone · FDA · approved · US · Biomedis International Ltd.
2023-01-18 — Neurontin · FDA · approved · US · Pfizer Inc. · Oncology
2023-01-17 — Celestone Soluspan · FDA · approved · US · Oncology
2023-01-17 — Versed · FDA · approved · US · Takeda Pharmaceutical Company Limited · Neuroscience
2023-01-17 — Versed · FDA · approved · US · Generic (originally Roche) · Neuroscience
2023-01-13 — Risperdal · FDA · approved · US · Johnson & Johnson (Janssen) · Neuroscience
2023-01-13 — RBP-7000 · FDA · approved · US · Indivior Inc. · Psychiatry
2023-01-13 — Versed · FDA · approved · US · Generic (originally Roche) · Neuroscience
2023-01-13 — Ketalar · FDA · approved · US · Ph Health · Metabolic
2023-01-13 — IV Ketamine · FDA · approved · US · Icahn School of Medicine at Mount Sinai · Psychiatry / Pain Management
2023-01-12 — Sandimmune · FDA · approved · US · Novartis · Oncology
2023-01-12 — Duramorph Pf · FDA · approved · US · Pfizer · Neuroscience
2023-01-12 — CYCLOSPORINE · FDA · approved · US
2023-01-10 — Arranon · FDA · approved · US · Novartis · Oncology
2023-01-10 — Mycophenolate · FDA · approved · US · Novartis · Immunology
2023-01-10 — OPC-34712 · FDA · approved · US · Otsuka Pharmaceutical Development & Commercialization, Inc. · Psychiatry/Neurology
2023-01-10 — Airsupra · FDA · approved · US · Massachusetts General Hospital · Other
2023-01-09 — BUPROPION · FDA · supplemented · US
2023-01-09 — Effient · FDA · approved · US · Cosette · Metabolic
2023-01-09 — P2Y12 · FDA · approved · US · Matthew Neal MD · Hematology
2023-01-06 — Leqembi · FDA · approved · US · Eisai · Immunology
2023-01-06 — Briviact · FDA · approved · US · UCB · Metabolic
2023-01-06 — LEQEMBI · FDA · approved · US · EISAI INC · Neuroscience
2023-01-06 — Leqembi · FDA · approved · US · Eisai · Immunology
2023-01-05 — Retin-A · FDA · approved · US · Bausch Health · Oncology
2023-01-05 — MEDROXYPROGESTERONE ACETATE · FDA · approved · US
2023-01-05 — Depo-Provera · FDA · approved · US · Pfizer · Oncology
2023-01-05 — Toviaz · FDA · approved · US · Pfizer · Metabolic
2023-01-05 — FLUPHENAZINE HYDROCHLORIDE · FDA · approved · US
2023-01-05 — Vimpat · FDA · approved · US · UCB · Neuroscience
2023-01-04 — Toviaz · FDA · approved · US · Pfizer · Metabolic
2023-01-04 — Toviaz · FDA · approved · US · Pfizer · Metabolic
2023-01-04 — Toviaz · FDA · approved · US · Pfizer · Metabolic
2023-01-03 — Depo-Medrol · FDA · approved · US · Pfizer · Oncology
2023-01-03 — Mifeprex · FDA · approved · US · Corcept Therap · Pain

Phase 3 trial readouts (0)

No Phase 3 readouts tracked in this month.

Patent expiries (2)

2023-01-24 — Vizamyl · 7351401 · US · GE HealthCare
2023-01-24 — Vizamyl · 8691185 · US · GE HealthCare

Subscribe to ongoing alerts

This page is a permanent monthly archive. For ongoing alerts as new events happen:

January 2023 — Pharma News Archive

Regulatory actions (71)

Phase 3 trial readouts (0)

Patent expiries (2)

Subscribe to ongoing alerts

See also